Wellington Management Group LLP Cuts Position in Regeneron Pharmaceuticals, Inc. $REGN

Posted by Stanley Muller on Aug 30th, 2026

Wellington Management Group LLP trimmed its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 30.9% in the 2nd quarter, HoldingsChannel reports. The fund owned 1,270,087 shares of the biopharmaceutical company’s stock after selling 567,372 shares during the quarter. Wellington Management Group LLP’s holdings in Regeneron Pharmaceuticals were worth $791,950,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in REGN. BlackRock Inc. purchased a new position in Regeneron Pharmaceuticals in the second quarter valued at about $5,682,636,000. Norges Bank purchased a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter valued at about $1,012,296,000. Price T Rowe Associates Inc. MD lifted its position in Regeneron Pharmaceuticals by 142.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,949,797 shares of the biopharmaceutical company’s stock valued at $1,504,991,000 after acquiring an additional 1,144,887 shares during the last quarter. Nuveen LLC boosted its stake in Regeneron Pharmaceuticals by 71.1% in the fourth quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company’s stock valued at $1,551,858,000 after acquiring an additional 835,240 shares in the last quarter. Finally, Legal & General Group Plc purchased a new position in Regeneron Pharmaceuticals in the second quarter worth $473,872,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock opened at $794.19 on Friday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The firm’s 50-day moving average is $717.52 and its two-hundred day moving average is $718.38. Regeneron Pharmaceuticals, Inc. has a 12 month low of $541.00 and a 12 month high of $847.00. The company has a market capitalization of $81.77 billion, a PE ratio of 19.63, a price-to-earnings-growth ratio of 1.35 and a beta of 0.22.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating the consensus estimate of $10.16 by $4.13. The business had revenue of $4.29 billion during the quarter, compared to analysts’ expectations of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The business’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $12.81 EPS. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Tuesday, August 18th will be issued a $0.94 dividend. The ex-dividend date is Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.29%.

Analyst Ratings Changes

Several brokerages have recently commented on REGN. Canaccord Genuity Group decreased their price objective on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating for the company in a report on Tuesday, May 19th. Truist Financial boosted their target price on Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Weiss Ratings reiterated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Wednesday, June 24th. Benchmark upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price target on the stock in a research note on Tuesday, July 7th. Finally, Piper Sandler decreased their price objective on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating for the company in a research report on Thursday, July 9th. Fifteen research analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $800.36.

Check Out Our Latest Stock Report on Regeneron Pharmaceuticals

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

Positive Sentiment: The FDA approved Pasatru (garetosmab) for adults with fibrodysplasia ossificans progressiva, an ultra-rare genetic disorder that causes abnormal bone growth. In a 56-week Phase 3 trial, the approved dose reduced disease-related bone formation, giving Regeneron a new commercial opportunity and strengthening its rare-disease pipeline. However, the small patient population likely limits the drug’s near-term earnings contribution. Can Regeneron’s Rare-Disease Win Move the Earnings Needle?
Neutral Sentiment: An investor letter highlighted Regeneron’s response to mixed results from its melanoma drug trials, including adjustments to its development strategy. The update offers limited new information but underscores the importance of replacing potential value lost from the failed program. Regeneron Adjusts Course Amid Mixed Results in Melanoma Drug Trials
Negative Sentiment: Several law firms announced or promoted a securities-fraud class action related to disclosures surrounding Regeneron’s failed Phase 3 melanoma trial. The failure reportedly erased approximately $11 billion in market capitalization and prompted allegations that investors were misled about the program. The repeated notices, all citing a September 14, 2026 lead-plaintiff deadline, add reputational and potential litigation-cost risks, although they do not represent a finding of wrongdoing. Regeneron Securities Fraud Class Action Filed Faruqi Shareholder Notice

Insider Buying and Selling

In other news, Director Kathryn Guarini sold 400 shares of the company’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $320,000.00. Following the transaction, the director owned 603 shares of the company’s stock, valued at $482,400. This represents a 39.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Y. Zoghbi sold 800 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the transaction, the director owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. This represents a 31.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 1,400 shares of company stock worth $1,090,030. Company insiders own 6.97% of the company’s stock.

About Regeneron Pharmaceuticals

(Free Report)

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.